MX2015012843A - Agentes quelantes de precursores de producto final de glicacion avanzada (age). - Google Patents

Agentes quelantes de precursores de producto final de glicacion avanzada (age).

Info

Publication number
MX2015012843A
MX2015012843A MX2015012843A MX2015012843A MX2015012843A MX 2015012843 A MX2015012843 A MX 2015012843A MX 2015012843 A MX2015012843 A MX 2015012843A MX 2015012843 A MX2015012843 A MX 2015012843A MX 2015012843 A MX2015012843 A MX 2015012843A
Authority
MX
Mexico
Prior art keywords
sequestrants
age
precursors
end product
advanced glycation
Prior art date
Application number
MX2015012843A
Other languages
English (en)
Inventor
J Miller Robert
Dhal Pradeep
Randall Holmes-Farley Stephen
Besev Magnus
T Papoulis Andrew
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2015012843A publication Critical patent/MX2015012843A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Los agentes quelantes de precursores de AGE comprenden aminas separadas por 2, 3 o 4 carbonos. Los agentes quelantes de precursores de AGE se pueden usar como agentes farmacéuticos y en composiciones farmacéuticas. Los agentes quelantes de precursores de AGE son precursores de AGE de unión particularmente útiles y dicarbonilos dietéticos en mamíferos en el tracto gastrointestinal para el tratamiento de enfermedades tales como nefropatía diabética, enfermedad renal crónica, aterosclerosis, apoplejía, cataratas, y enfermedad de Alzheimer.
MX2015012843A 2013-03-15 2014-03-12 Agentes quelantes de precursores de producto final de glicacion avanzada (age). MX2015012843A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792719P 2013-03-15 2013-03-15
PCT/US2014/024436 WO2014150873A1 (en) 2013-03-15 2014-03-12 Sequestrants of advanced glycation end product (age) precursors

Publications (1)

Publication Number Publication Date
MX2015012843A true MX2015012843A (es) 2016-08-08

Family

ID=50439508

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012843A MX2015012843A (es) 2013-03-15 2014-03-12 Agentes quelantes de precursores de producto final de glicacion avanzada (age).

Country Status (24)

Country Link
US (2) US20160024233A1 (es)
EP (1) EP2968403A1 (es)
JP (4) JP2016512830A (es)
KR (1) KR20150130492A (es)
CN (1) CN105188718A (es)
AR (1) AR095593A1 (es)
AU (2) AU2014235500A1 (es)
BR (1) BR112015023404A8 (es)
CA (1) CA2906501A1 (es)
CL (1) CL2015002624A1 (es)
CR (1) CR20150545A (es)
DO (1) DOP2015000221A (es)
EA (1) EA201591733A1 (es)
HK (1) HK1220607A1 (es)
IL (1) IL241406A0 (es)
MA (1) MA38487A1 (es)
MX (1) MX2015012843A (es)
PE (1) PE20151766A1 (es)
PH (1) PH12015502019A1 (es)
SG (2) SG10201707590XA (es)
TN (1) TN2015000390A1 (es)
TW (1) TW201521744A (es)
UY (1) UY35441A (es)
WO (1) WO2014150873A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41202A (fr) * 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
MX2020002048A (es) * 2017-08-31 2020-09-21 Cytosorbents Corp Reduccion de productos finales de glicacion avanzada a partir de fluidos corporales.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
AU2002257145B2 (en) * 2001-04-18 2005-06-02 Genzyme Corporation Method for lowering serum glucose
AU2003263010A1 (en) * 2003-09-02 2005-04-21 Genzyme Corporation Method for reducing vascular inflammation
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
MXPA06009363A (es) * 2004-02-17 2007-01-26 Dynamis Therapeutics Inc Fructosaamina 3 cinasa y la formacion de colageno y elastina.
FR2883873B1 (fr) * 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
AU2011220742B2 (en) * 2010-02-24 2016-02-25 Relypsa, Inc. Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants

Also Published As

Publication number Publication date
KR20150130492A (ko) 2015-11-23
SG11201506413PA (en) 2015-09-29
AU2014235500A1 (en) 2015-11-05
BR112015023404A8 (pt) 2019-12-03
JP2016512830A (ja) 2016-05-09
CR20150545A (es) 2015-12-01
JP2022037143A (ja) 2022-03-08
US20160024233A1 (en) 2016-01-28
HK1220607A1 (zh) 2017-05-12
BR112015023404A2 (pt) 2017-07-18
JP2018135365A (ja) 2018-08-30
EA201591733A1 (ru) 2016-01-29
PH12015502019A1 (en) 2016-01-11
IL241406A0 (en) 2015-11-30
CL2015002624A1 (es) 2016-03-11
EP2968403A1 (en) 2016-01-20
SG10201707590XA (en) 2017-11-29
UY35441A (es) 2014-10-31
PE20151766A1 (es) 2015-12-11
CN105188718A (zh) 2015-12-23
JP2020055850A (ja) 2020-04-09
AU2019201259A1 (en) 2019-03-14
TW201521744A (zh) 2015-06-16
CA2906501A1 (en) 2014-09-25
WO2014150873A1 (en) 2014-09-25
TN2015000390A1 (en) 2017-01-03
DOP2015000221A (es) 2015-12-15
AR095593A1 (es) 2015-10-28
MA38487A1 (fr) 2017-12-29
US20180265613A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
TN2015000278A1 (en) Autotaxin inhibitors
PH12016500094A1 (en) Autotaxin inhibitors
PH12015501291B1 (en) Functionalized exendin-4 derivatives
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
MX2015009104A (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
PH12014501991B1 (en) Phenicol antibacterials
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
MX2015015518A (es) Metodos y composiciones para el tratamiento del cancer.
HRP20181362T1 (hr) Kompenzacija za farmaceutsku, nutritivnu ili kozmetičku upotrebu na bazi flavonoida koja ima pojačano antioksidativno djelovanje
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
WO2014044794A3 (en) Pharmaceutical composition
MX357284B (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
WO2015059463A3 (en) Treatment of beta-catenin related diseases8
MX2017007054A (es) Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior.
IN2014DN07326A (es)
WO2014147503A3 (en) Anti-bag3 antibodies for therapeutic use
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias
PH12015502019A1 (en) Sequestrants of advanced glycation end product (age) precursors
MX2016001691A (es) Moleculas de union al receptor bag3 para uso como un medicamento.
EP3503745A4 (en) DIET DIET Macro / Micronutrient Supplement for Kidney Dialysis Patients
NZ703573A (en) Feijoa fruit extract
WO2017079403A3 (en) Polymeric nanoparticles
BR112017007112A2 (pt) compostos de 1,2-benzotiazol para o tratamento de distúrbios renais
CN301991818S (zh) 家具连接件（易系列）
IN2013MU03429A (es)